What are Autologous Cellular Immunotherapy [EPC] drugs?

Autologous Cellular Immunotherapy [EPC] drugs are pharmacologic agents that share a common mechanism (typically targeting PAP). 1 are currently marketed, with 3 more in clinical development.

What are the marketed Autologous Cellular Immunotherapy [EPC] drugs?

Marketed Autologous Cellular Immunotherapy [EPC] drugs include SIPULEUCEL-T.

Autologous Cellular Immunotherapy [EPC]

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 3 in Phase 3

This page covers all Autologous Cellular Immunotherapy [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PAP.

Targets

PAP

Marketed (1)

SIPULEUCEL-T
PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers.

Phase 3 pipeline (3)

DC-CIK · Guangxi Medical University · Oncology
DC-CIK is a dendritic cell-cytokine induced killer cell immunotherapy that activates and expands autologous immune cells to target and destroy cancer cells.
irradiated RBC · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Oncology / Immunology
Irradiated red blood cells act as an immunogenic cellular vaccine to stimulate anti-tumor immune responses.
Autologous monocytes · Aivita Biomedical, Inc. · Immunology; Regenerative Medicine
Autologous monocytes are a patient's own immune cells that are isolated, potentially modified or activated ex vivo, and reinfused to enhance immune function and promote tissue repair.

Patent intelligence

cellular immunotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates